Study drug for ROS1-positive lung or solid tumors
Part of Cancer clinical trials.
This Phase 1/2 study tests zidesamtinib (NVL-520), a medicine meant to attack cancers that have a ROS1 genetic change. It’s for people with advanced or metastatic ROS1-rearranged NSCLC (lung cancer) and, in one group, other solid tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older (or 12+ for a specific smaller tumor group).
- Your cancer has a confirmed ROS1 rearrangement from a test of tumor samples.
- Your cancer is advanced or has spread (locally advanced or metastatic).
- You either have “evaluable” tumors (Phase 1) or “measurable” tumors by scan rules (Phase 2).
- You’ve had prior cancer treatment (with one Phase 2 group exception).
- Your organs and bone marrow are strong enough for treatment based on blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests neladalkib (NVL-655), a medicine designed to attack ALK-positive cancer. It may help people with advanced ALK-mutated or ALK-rearranged solid tumors, especially ALK-positive non-small cell lung cancer.
This trial tests a new oral drug called NVL-330 for people with advanced NSCLC whose tumors have a specific change in the HER2 gene. The goal is to see if the drug can shrink or slow the growth of the cancer.
This program provides access to an experimental drug (zidesamtinib) for people with advanced ROS1-positive cancer who have run out of other options. The study aims to give these patients a chance to try a new targeted therapy that may help control the cancer.
This trial studies an investigational pill (XZP-5955) for solid tumors that have specific gene changes: NTRK or ROS1 fusions. It is meant for people whose cancer is advanced or has spread, and who may not have good standard treatment options.
This Phase 2 trial tests ZEN003694 in people with squamous (a type of) lung cancer that has returned or spread. It’s designed for tumors that have a certain gene change, and it may offer a new treatment option after prior chemotherapy and immunotherapy.
This study tests a new targeted therapy for people with a specific type of advanced lung cancer that has not been treated before. The drug JYP0322 may help shrink tumors or slow cancer growth, and the study checks if it is safe and effective.
Hear when a new Locally Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.